James Huang has over 30 years of biotech experience and is the Founder and Managing Partner
Prior to Panacea Venture, James joined Kleiner Perkins (KPCB) China as a Managing Partner in 2011 and focused on the firm’s life sciences practice. His main investment interests are innovation around China’s growing healthcare markets and helping entrepreneurs build companies
Before joining KPCB China, James was a managing partner at Vivo Ventures, a venture capital firm specializing in life sciences investments. While at Vivo Ventures, James led numerous investments in China. Before joining Vivo Ventures in 2007, James was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, he also held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Myers Squibb and ALZA Corp. (acquired by Johnson & Johnson)
James is a director of numerous boards, including Kindstar Global, TacTiva Therapeutics, TriArm Therapeutics, Chime Biologics, Eos, GT Aperion, Domain, Asia Pacific Medical and XWPharma
James received an MBA from the Stanford Graduate School of Business and a B.S. in Chemical Engineering from the University of California, Berkeley.
Partners make up the core of the investing team and collectively have more than 100 years of VC experience